Want to see DHC full AI Analyst Report?
Segment Income Breakdown
Operating income or loss separated by segment, showing which asset classes or operations generate the strongest margins and free cash flow. Helps identify underperforming units, assess dividend sustainability, and understand where management may target cost control or capital deployment.SHOP’s segment income is choppy with periodic deep deficits, but operational momentum (occupancy gains, ~5–6% rate growth, meaningful expense cuts) explains management’s confidence that SHOP NOI will outpace prior expectations through the year despite seasonal softness and ongoing capex. The Medical Office & Life Science Portfolio flipped into positive income late 2025, reflecting strong lease renewals and above‑market rent resets—a healthier cash profile but one that still faces near‑term rollover/vacancy exposure and recurring CapEx needs that could constrain cash conversion.
Date | SHOP | Medical Office & Life Science Portfolio |
|---|---|---|
Jun 30, 2026 | $201.00K | $9.35M |
Mar 31, 2026 | -$11.06M | $9.46M |
Dec 31, 2025 | -$7.93M | $22.38M |
Sep 30, 2025 | -$60.57M | -$46.99M |
Jun 30, 2025 | -$38.41M | -$5.28M |
Mar 31, 2025 | -$3.09M | -$18.74M |
Dec 31, 2024 | -$29.57M | -$14.23M |
Sep 30, 2024 | -$19.96M | -$14.48M |
Jun 30, 2024 | -$17.99M | -$30.85M |
Mar 31, 2024 | -$22.28M | -$7.11M |